Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R)diabetes program.
Yesterday after the closing bell, Nemaura filed material with the SEC for the Benzinga conference that includes information on its new beta program under the brand name MiBoKo, which appears to be a mass market consumer product for metabolic health. For more information on Nemaura and its products, visit the company’s website at www.NemauraMedical.com
To view IBN’s virtual coverage of Benzinga’s Healthcare Small Cap Conference, visit https://events.investorbrandnetwork.com/2021/benzinga-healthcare-conference/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at this week’s Benzinga conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]